Motus GI Holdings, Inc. (MOTS): Price and Financial Metrics
GET POWR RATINGS... FREE!
MOTS POWR Grades
- MOTS scores best on the Growth dimension, with a Growth rank ahead of 81.22% of US stocks.
- MOTS's strongest trending metric is Growth; it's been moving up over the last 132 days.
- MOTS's current lowest rank is in the Stability metric (where it is better than 0.47% of US stocks).
MOTS Stock Summary
- MOTS has a market capitalization of $3,910,701 -- more than approximately only 1.15% of US stocks.
- The volatility of MOTUS GI HOLDINGS INC's share price is greater than that of 96.45% US stocks with at least 200 days of trading history.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for MOTS comes in at -189.69% -- higher than that of only 3.37% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to MOTUS GI HOLDINGS INC, a group of peers worth examining would be RXST, NPCE, SOPH, AIRG, and BASE.
- Visit MOTS's SEC page to see the company's official filings. To visit the company's web site, go to www.motusgi.com.
MOTS Valuation Summary
- MOTS's EV/EBIT ratio is -0.1; this is 101.52% lower than that of the median Healthcare stock.
- Over the past 62 months, MOTS's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for MOTS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MOTS | 2023-03-24 | 6.7 | 5.1 | -0.2 | -0.1 |
| MOTS | 2023-03-23 | 6.5 | 5.0 | -0.2 | -0.1 |
| MOTS | 2023-03-22 | 6.9 | 5.2 | -0.2 | -0.2 |
| MOTS | 2023-03-21 | 6.9 | 5.2 | -0.2 | -0.2 |
| MOTS | 2023-03-20 | 6.7 | 5.1 | -0.2 | -0.1 |
| MOTS | 2023-03-17 | 7.0 | 5.4 | -0.2 | -0.2 |
MOTS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- MOTS has a Quality Grade of F, ranking ahead of 2.21% of graded US stocks.
- MOTS's asset turnover comes in at 0.008 -- ranking 170th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows MOTS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.008 | -1.391 | -8.260 |
| 2021-03-31 | 0.005 | -3.083 | -7.460 |
| 2020-12-31 | 0.004 | -4.061 | -8.708 |
| 2020-09-30 | 0.006 | 0.112 | -5.005 |
| 2020-06-30 | 0.005 | -0.321 | -3.413 |
| 2020-03-31 | 0.005 | -0.231 | -3.489 |
MOTS Price Target
For more insight on analysts targets of MOTS, see our MOTS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $2.03 | Average Broker Recommendation | 1.25 (Strong Buy) |
MOTS Stock Price Chart Interactive Chart >
MOTS Price/Volume Stats
| Current price | $0.93 | 52-week high | $8.10 |
| Prev. close | $0.88 | 52-week low | $0.68 |
| Day low | $0.93 | Volume | 2,393 |
| Day high | $0.95 | Avg. volume | 82,205 |
| 50-day MA | $0.95 | Dividend yield | N/A |
| 200-day MA | $2.36 | Market Cap | 2.78M |
Motus GI Holdings, Inc. (MOTS) Company Bio
Motus GI Holdings, Inc., a development stage company, engages in developing single-use medical device systems in the United States. It is developing Pure-Vu system that integrates with existing colonoscopes to cleanse poorly prepped colons during the colonoscopy procedure. The company is based in Tirat Carmel, Israel.
Latest MOTS News From Around the Web
Below are the latest news stories about MOTUS GI HOLDINGS INC that investors may wish to consider to help them evaluate MOTS as an investment opportunity.
Motus GI Holdings Looks For Strategic AlternativesMotus GI Holdings Inc (NASDAQ: MOTS) has initiated a process to explore a range of strategic and financing alternatives. As part of this process, the company has engaged Lake Street Capital Markets LLC as an advisor. In addition, the board has approved a strategic restructuring program to preserve capital by initially reducing quarterly operating costs by approximately 35%. Motus plans to eliminate approximately 45% of its workforce, which is expected to be completed during the first quarter of |
Motus GI Announces Exploration of Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring PlanLake Street Capital Markets LLC engaged to act as an advisor to the CompanyBoard of Directors approved restructuring program with the objective of preserving capital to align with strategic process timelineManagement plans to continue providing sales and support for existing Pure-Vu EVS customers and pipeline opportunities in contracted health systemsCompany to move forward with regulatory process and commercial readiness for Pure-Vu EVS Gastro FORT LAUDERDALE, Fla., Jan. 10, 2023 (GLOBE NEWSWIR |
Motus GI Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical TestsPre-clinical tests show enhanced functionality of Pure-Vu EVS that can enable physicians to overcome common visualization challenges encountered during emergency upper GI bleeding proceduresAdditional pre-clinical and clinical tests of Pure-Vu EVS System are planned in 1H 2023; development program on track to submit 510(K) application to FDA in 2H 2023Company intends to evaluate potential strategic distribution and licensing partnerships in U.S. and abroad FORT LAUDERDALE, Fla., Dec. 21, 2022 (G |
Motus GI Holdings Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagMotus GI Holdings ( NASDAQ:MOTS ) Third Quarter 2022 Results Key Financial Results Net loss: US$4.96m (loss widened by... |
Analysts Are Bullish on These Healthcare Stocks: Syros Pharmaceuticals (SYRS), Motus Gi Holdings (MOTS)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Syros Pharmaceuticals (SYRS – Research Report), Motus Gi Holdings (MOTS – Research Report) and TransCode Therapeutics (RNAZ – Research Report) with bullish sentiments. Syros Pharmaceuticals (SYRS) H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Syros Pharmaceuticals today and set a price target of $20.00. The company's shares closed last Monday at $3.66, close to its 52-week low of $3.52. According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -28.1% and a 24.4% success rate. |
MOTS Price Returns
| 1-mo | 1.64% |
| 3-mo | 10.71% |
| 6-mo | -62.04% |
| 1-year | -87.52% |
| 3-year | -93.26% |
| 5-year | -98.96% |
| YTD | 10.71% |
| 2022 | -91.01% |
| 2021 | -50.74% |
| 2020 | -58.60% |
| 2019 | -26.37% |
| 2018 | N/A |
Continue Researching MOTS
Want to see what other sources are saying about Motus GI Holdings Inc's financials and stock price? Try the links below:Motus GI Holdings Inc (MOTS) Stock Price | Nasdaq
Motus GI Holdings Inc (MOTS) Stock Quote, History and News - Yahoo Finance
Motus GI Holdings Inc (MOTS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...